NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, News, & Analysis

$60.24
-2.36 (-3.77 %)
(As of 06/25/2019 02:47 AM ET)
Today's Range
$60.06
Now: $60.24
$62.55
50-Day Range
$54.93
MA: $59.90
$66.09
52-Week Range
$37.44
Now: $60.24
$90.98
Volume385,300 shs
Average Volume562,970 shs
Market Capitalization$3.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.49 million
Book Value$12.04 per share

Profitability

Net Income$-197,610,000.00
Net Margins-550.30%

Miscellaneous

EmployeesN/A
Market Cap$3.46 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its earnings results on Monday, May, 6th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.73) by $0.09. The biopharmaceutical company had revenue of $18.17 million for the quarter, compared to the consensus estimate of $18.75 million. Ultragenyx Pharmaceutical had a negative return on equity of 51.00% and a negative net margin of 550.30%. The business's revenue was up 70.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 earnings per share. View Ultragenyx Pharmaceutical's Earnings History.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Ultragenyx Pharmaceutical.

What price target have analysts set for RARE?

15 analysts have issued 12-month price targets for Ultragenyx Pharmaceutical's shares. Their predictions range from $59.00 to $95.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $78.9333 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.

What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

Headlines about RARE stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the next few days. View News Stories for Ultragenyx Pharmaceutical.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Celgene (CELG), Netflix (NFLX), Exelixis (EXEL), Square (SQ), Alexion Pharmaceuticals (ALXN), Nike (NKE), Activision Blizzard (ATVI), GALAPAGOS NV/S (GLPG), Portola Pharmaceuticals (PTLA) and CVS Health (CVS).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.28%), FMR LLC (4.38%), First Trust Advisors LP (3.23%), Federated Investors Inc. PA (3.05%), Clearbridge Investments LLC (1.76%) and Pictet Asset Management Ltd. (1.01%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Which major investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Pictet Asset Management Ltd., Xact Kapitalforvaltning AB, WS Management Lllp, Los Angeles Capital Management & Equity Research Inc., Bank of Montreal Can and Oppenheimer Asset Management Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Shalini Sharp and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Which major investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, First Trust Advisors LP, BlackRock Inc., SG Americas Securities LLC, Sector Gamma AS, Rothschild & Co. Asset Management US Inc., Fosun International Ltd and Laurion Capital Management LP. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $60.24.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $3.46 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-197,610,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]


MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  640 (Thanks for Voting!)
Underperform Votes:  297 (Thanks for Voting!)
Total Votes:  937
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel